These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 21047491)

  • 41. Safety of 10 min infusion of bevacizumab in combination with 5FU-based chemotherapy in non-selected metastatic colorectal cancer patients.
    Coriat R; Mir O; Chaussade S; Goldwasser F
    Dig Liver Dis; 2011 Mar; 43(3):248-9. PubMed ID: 21145299
    [No Abstract]   [Full Text] [Related]  

  • 42. [Efficacy of chemotherapy combined with bevacizumab for metastatic colorectal cancer].
    Momoi A; Motomura S; Hashimoto C; Takasaki H; Takemura S; Takagi S; Akaike M
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):79-83. PubMed ID: 21368462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Efficacy of chemotherapy combined with bevacizumab for unresectable advanced or recurrent colorectal cancer].
    Watanabe T; Nishiwaki N; Kajiwara Y; Okamoto T; Miyamoto M; Kohjima T; Watanabe Y; Yoshino K; Kawai T; Toda K; Nobuhisa T; Endo Y; Matsumoto Y; Watanabe N; Kai K; Sato S
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):71-4. PubMed ID: 23306921
    [TBL] [Abstract][Full Text] [Related]  

  • 44. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
    J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Current status and perspectives of biologics in the treatment of metastatic colorectal cancer].
    Takiuchi H
    Nihon Rinsho; 2010 Oct; 68(10):1866-70. PubMed ID: 20954331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.
    Bates DO; Catalano PJ; Symonds KE; Varey AH; Ramani P; O'Dwyer PJ; Giantonio BJ; Meropol NJ; Benson AB; Harper SJ
    Clin Cancer Res; 2012 Nov; 18(22):6384-91. PubMed ID: 23104894
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Multicentre phase II study of XELOX with bevacizumab in late-stage elderly patients with unresectable advanced/recurrent colorectal cancer: an ASCA study.
    Oba K; Matsuoka M; Satoh T; Muro K; Oriuchi N; Sakamoto J; Mishima H
    Jpn J Clin Oncol; 2011 Jan; 41(1):134-8. PubMed ID: 20819834
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of colorectal cancer with and without bevacizumab: a phase III study.
    Stathopoulos GP; Batziou C; Trafalis D; Koutantos J; Batzios S; Stathopoulos J; Legakis J; Armakolas A
    Oncology; 2010; 78(5-6):376-81. PubMed ID: 20798560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
    Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
    JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pembrolizumab for Previously Treated Advanced or Metastatic Urothelial Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Gallacher D; Armoiry X; Auguste P; Court R; Mantopoulos T; Patterson J; De Santis M; Cresswell J; Mistry H
    Pharmacoeconomics; 2019 Jan; 37(1):19-27. PubMed ID: 30030817
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bevacizumab and ovarian cancer.
    Sato S; Itamochi H
    Curr Opin Obstet Gynecol; 2012 Feb; 24(1):8-13. PubMed ID: 22123222
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. First-line fluoropyrimidine plus bevacizumab followed by irinotecan-escalation versus initial fluoropyrimidine, irinotecan and bevacizumab in patients with metastatic colorectal cancer - Final survival and per-protocol analysis of the randomised XELAVIRI trial (AIO KRK 0110).
    Stahler A; Modest DP; Fischer von Weikersthal L; Kaiser F; Decker T; Held S; Graeven U; Schwaner I; Denzlinger C; Schenk M; Kurreck A; Heinrich K; Gießen-Jung C; Neumann J; Kirchner T; Jung A; Stintzing S; Heinemann V
    Eur J Cancer; 2022 Sep; 173():194-203. PubMed ID: 35940054
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.
    Bagust A; Greenhalgh J; Boland A; Fleeman N; McLeod C; Dickson R; Dundar Y; Proudlove C; Shaw R
    Pharmacoeconomics; 2010; 28(6):439-48. PubMed ID: 20465313
    [TBL] [Abstract][Full Text] [Related]  

  • 55. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
    Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; Zheng X; Wang QJ; Li YQ; Xiang T; Zhou L; Yang SN; Wu C; Huang RX; He J; Du WJ; Chen LJ; Wu YN; Xu B; Shen Q; Zhang Y; Jiang JT; Ren XB; Xia JC
    Signal Transduct Target Ther; 2024 Apr; 9(1):79. PubMed ID: 38565886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival for metastatic colorectal cancer in the bevacizumab era: a population-based analysis.
    Renouf DJ; Lim HJ; Speers C; Villa D; Gill S; Blanke CD; O'Reilly SE; Kennecke H
    Clin Colorectal Cancer; 2011 Jun; 10(2):97-101. PubMed ID: 21859560
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer: results from a large treatment observational cohort study.
    Kabbinavar FF; Flynn PJ; Kozloff M; Ashby MA; Sing A; Barr CE; Grothey A
    Eur J Cancer; 2012 May; 48(8):1126-32. PubMed ID: 22424880
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and Safety of Bevacizumab Combined With Fluoropyrimidine Monotherapy for Unfit or Older Patients With Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Pinto C; Antonuzzo L; Porcu L; Aprile G; Maiello E; Masi G; Petrelli F; Scartozzi M; Torri V; Barni S
    Clin Colorectal Cancer; 2017 Jun; 16(2):e61-e72. PubMed ID: 27687553
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Adams RA; Meade AM; Seymour MT; Wilson RH; Madi A; Fisher D; Kenny SL; Kay E; Hodgkinson E; Pope M; Rogers P; Wasan H; Falk S; Gollins S; Hickish T; Bessell EM; Propper D; Kennedy MJ; Kaplan R; Maughan TS;
    Lancet Oncol; 2011 Jul; 12(7):642-53. PubMed ID: 21641867
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
    Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
    Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.